<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hereditary angioedema: Short-term prophylaxis before procedures or stressful events to prevent angioedema episodes</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hereditary angioedema: Short-term prophylaxis before procedures or stressful events to prevent angioedema episodes</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hereditary angioedema: Short-term prophylaxis before procedures or stressful events to prevent angioedema episodes</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bruce Zuraw, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Henriette Farkas, MD, PhD, DSc</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sarbjit Saini, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 29, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3814766223"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent angioedema without wheals [<a href="#rid1">1</a>]. All forms of HAE are characterized by recurrent episodes of angioedema without pruritus or urticaria, which most often affect the skin and/or mucosal tissues of the upper respiratory and gastrointestinal tracts. Although swelling resolves spontaneously in two to five days in the absence of treatment, angioedema can often be temporarily debilitating, and laryngeal angioedema may cause fatal asphyxiation. There are several different forms of HAE. The recommendations in this topic apply to those due to C1 inhibitor (C1-INH) deficiency.</p><p>Dental and medical procedures, emotional stress, hormonal changes (related to menstruation or pregnancy), infections, and medications (including oral contraceptives and ACE-inhibitors) are among the most common stimuli that can trigger episodes of angioedema. The various prophylactic therapies that are used prior to prevent HAE attacks ("preprocedural" prophylaxis) will be reviewed here. Long-term prophylaxis to reduce the frequency and severity of angioedema episodes and other issues in the diagnosis and management of HAE are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8100.html" rel="external">"Hereditary angioedema (due to C1 inhibitor deficiency): General care and long-term prophylaxis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8104.html" rel="external">"Hereditary angioedema: Acute treatment of angioedema attacks"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8103.html" rel="external">"Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8098.html" rel="external">"Hereditary angioedema (due to C1 inhibitor deficiency): Pathogenesis and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16529.html" rel="external">"Hereditary angioedema with normal C1 inhibitor"</a>.)</p><p></p><p class="headingAnchor" id="H3814766289"><span class="h1">INDICATIONS FOR SHORT-TERM PROPHYLAXIS</span><span class="headingEndMark"> — </span>The most common indications for short-term prophylaxis are invasive procedures (especially dental/intraoral surgery, endotracheal intubation, or endoscopies) or anticipated stressful events [<a href="#rid2">2-4</a>]. Prophylaxis may also be given for a brief period of time (ie, "extended" short-term/intermittent prophylaxis) for travel to remote areas or countries in which there may not be ready access to health care or for a period of weeks or months during which increased stress is anticipated (eg, students during exam periods) [<a href="#rid5">5</a>].</p><p>The need for short-term prophylaxis is influenced by the availability of one of the "on-demand" treatments: C1 inhibitor (C1-INH) concentrates, <a class="drug drug_general" data-topicid="16808" href="/z/d/drug information/16808.html" rel="external">icatibant</a>, or <a class="drug drug_general" data-topicid="9035" href="/z/d/drug information/9035.html" rel="external">ecallantide</a>. If none of the on-demand therapies are available, then pre-procedural short-term prophylaxis is especially important. Mechanisms of action, efficacy, dosing, and administration of on-demand therapies are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8104.html" rel="external">"Hereditary angioedema: Acute treatment of angioedema attacks", section on 'First-line agents: Dosing, efficacy, and adverse reactions'</a>.)</p><p class="headingAnchor" id="H3013787820"><span class="h2">Patients already on long-term prophylaxis</span><span class="headingEndMark"> — </span>For patients already receiving long-term prophylaxis with intravenous C1-INH or androgens, dosing can be modified prior to a procedure. For example, patients receiving regular intravenous injections of plasma-derived C1-INH (<a class="drug drug_general" data-topicid="8998" href="/z/d/drug information/8998.html" rel="external">pdC1-INH</a>) can arrange to have an injection immediately before the procedure, or patients taking androgens can increase the dose for five days prior to the procedure and continued for additional two to three days after procedure [<a href="#rid3">3,4</a>]. The risk of procedural angioedema in patients receiving subcutaneous pdC1-INH or <a class="drug drug_general" data-topicid="118876" href="/z/d/drug information/118876.html" rel="external">lanadelumab</a> is unknown, and because of this uncertainty, the authors will often recommend an injection of intravenous pdC1-INH prior to the procedure to be safe. </p><p class="headingAnchor" id="H2559109945"><span class="h2">Risk associated with specific procedures</span><span class="headingEndMark"> — </span>The highest-risk procedures are intubation, oral surgery, and major dental work (ie, cutting of tissue or injections of anesthetics), which can trigger symptoms in most patients [<a href="#rid6">6,7</a>]. These procedures can induce both cutaneous and upper airway edema. Short-term prophylaxis should always be administered prior to these procedures, even if the patient has access to acute therapies. </p><p class="headingAnchor" id="H2823606978"><span class="h3">Dental work</span><span class="headingEndMark"> — </span>Because of the precautions required, many patients with HAE report hurdles to obtaining appropriate dental care. However, the treatment of severe oral pathology can have a positive impact on the course of the disease [<a href="#rid8">8</a>]. </p><p>In a series of 577 tooth extractions when prophylaxis was not given, 21.5 percent of the extractions were followed by angioedema symptoms with 116 of the 124 episodes resulting in swelling of the face, upper airway, or a combination [<a href="#rid9">9</a>]. Symptoms occurred up to 72 hours after the procedure, with a mean time to onset of 14 hours. Among procedures in which patients received prophylaxis with <a class="drug drug_general" data-topicid="8998" href="/z/d/drug information/8998.html" rel="external">pdC1-INH</a> concentrate, 12.5 percent resulted in swelling, at a mean of eight hours after the procedure. The fewest attacks were seen in patients receiving 1000 units of pdC1-INH concentrate, administered one hour before the procedure.</p><p>Minor dental procedures (eg, routine cleanings, filling of cavities, crown placement, restorative work) are lower risk, and the patient's past response to similar interventions can guide the decision to give prophylaxis. However, patients vary in their sensitivity to procedure-induced swelling. Those who have developed swelling in similar situations in the past should receive preprocedural prophylaxis in the future, even for minor interventions. Those who have tolerated these procedures in the past are likely to continue to do so. If a patient's tolerance for a given procedure is unknown, short-term prophylaxis is indicated.</p><p class="headingAnchor" id="H3814766315"><span class="h2">Typical timing of onset of symptoms</span><span class="headingEndMark"> — </span>HAE attacks can occur anywhere from hours to several days after a procedure, and typically begin within 48 hours of the intervention [<a href="#rid7">7,9,10</a>]. Patients should be advised that swelling often occurs one day or so <strong>after</strong> the procedure, and a specific plan of treatment should be in place for symptoms that arise during this period, including access to on-demand therapies. In the study of tooth extractions discussed above, patients who received prophylaxis with <a class="drug drug_general" data-topicid="8998" href="/z/d/drug information/8998.html" rel="external">pdC1-INH</a> concentrate were at highest risk during the 12 hours after the procedure [<a href="#rid9">9</a>]. Some attacks began during the night while the patients were asleep and were therefore recognized later than if they had occurred during waking hours. For this reason, some experts advise patients to schedule procedures as early as possible in the day.</p><p class="headingAnchor" id="H3814766679"><span class="h1">AVAILABLE AGENTS</span><span class="headingEndMark"> — </span>The agents that can be used for short-term prophylaxis are C1 inhibitor (C1-INH) concentrate, attenuated androgens, and plasma products. These are reviewed here, with availability, efficacy, and adverse effects [<a href="#rid11">11</a>].</p><p>Note that <a class="drug drug_general" data-topicid="9035" href="/z/d/drug information/9035.html" rel="external">ecallantide</a> (a kallikrein inhibitor) and <a class="drug drug_general" data-topicid="16808" href="/z/d/drug information/16808.html" rel="external">icatibant</a> (a bradykinin B2-receptor antagonist), which are other on-demand therapies, are <strong>not</strong> used before procedures, because these two agents have short half-lives (six hours or less). Thus, they are only used to stop an HAE attack once it has commenced. Their utility as prophylactic agents has not been defined. Only a single report has been published on the use of a bradykinin B2-receptor antagonist for short-term prophylaxis [<a href="#rid12">12</a>].</p><p><a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">Tranexamic acid</a> (TA), an antifibrinolytic agent, has been recommended by some guidelines but without theoretical rationale or practical evidence of efficacy. Therefore, the authors do not recommend use of TA for short-term prophylaxis.</p><p class="headingAnchor" id="H1486741557"><span class="h2">Comparative efficacy</span><span class="headingEndMark"> — </span>Overall, C1-INH concentrate is likely the most effective therapy for short-term prophylaxis, followed by attenuated androgens. Although there are no controlled trials directly comparing the efficacy of different therapies for short-term prophylaxis, a retrospective analysis found that post-procedural HAE attacks occurred in fewer patients treated with prophylactic <a class="drug drug_general" data-topicid="8998" href="/z/d/drug information/8998.html" rel="external">pdC1-INH</a> concentrate, compared with those who received <a class="drug drug_general" data-topicid="9321" href="/z/d/drug information/9321.html" rel="external">danazol</a> (6 versus 13 percent, respectively) [<a href="#rid7">7</a>]. </p><p>Evaluation of the efficacy of various agents in short-term prophylaxis is complicated by the unpredictability of HAE attacks. Procedures that have triggered attacks in a given patient do not necessarily do so reproducibly, and major interventions that would be expected to precipitate attacks in most patients may not, even in the absence of prophylaxis. A registry-based survey has provided some additional real world data [<a href="#rid6">6</a>]. Because of this inherent unpredictability, it is prudent to give prophylaxis if there is any uncertainty about the risk of an HAE attack.</p><p class="headingAnchor" id="H3814766699"><span class="h2">C1 inhibitor concentrate</span><span class="headingEndMark"> — </span>Plasma-derived C1 inhibitor (<a class="drug drug_general" data-topicid="8998" href="/z/d/drug information/8998.html" rel="external">pdC1-INH</a>) concentrate may be administered intravenously for short-term prophylaxis. This is also the treatment of choice for short-term prophylaxis during pregnancy [<a href="#rid13">13</a>]. Note that subcutaneous administration has not been studied for short-term prophylaxis and is not recommended.</p><p>In the United States, two human plasma-derived products (<a class="drug drug_general" data-topicid="8998" href="/z/d/drug information/8998.html" rel="external">pdC1-INH</a>) are available for intravenous administration, Cinryze and Berinert. Cinryze is US Food and Drug Administration (FDA)-approved for long-term prophylaxis, and Berinert for acute treatment of HAE attacks; both are effective for short-term prophylaxis. Both Cinryze and Berinert are approved for short-term prophylaxis in Europe.</p><p class="headingAnchor" id="H2612386824"><span class="h3">Dose and timing</span><span class="headingEndMark"> — </span>Based on a small number of publications, a dose of 500 to 1000 units is effective in most children and adults [<a href="#rid14">14,15</a>]. The risk of angioedema has been shown to be closely linked to the plasma functional C1-INH level, with a level of 50 percent of normal offering near complete protection [<a href="#rid16">16</a>]. Therefore, the authors recommend that the dose of <a class="drug drug_general" data-topicid="8998" href="/z/d/drug information/8998.html" rel="external">pdC1-INH</a> be sufficient to achieve a functional C1-INH level of ≥50 percent at the time of the procedure, an outcome typically achieved immediately after a dose of 20 international units (IU) per kg body weight.  </p><p>C1-INH concentrate is ideally given one hour prior to or immediately before the major procedure. However, if necessary, dosing can be given further in advance of the procedure. The half-life of a single weight-based dose of <a class="drug drug_general" data-topicid="8998" href="/z/d/drug information/8998.html" rel="external">pdC1-INH</a> is 30 to 39 hours [<a href="#rid17">17,18</a>], and in the study discussed above, administration up to 24 hours before was sufficient to prevent attacks [<a href="#rid14">14</a>]. However, a dose of pdC1-INH could conceivably be consumed within 24 hours in some patients, and the median time to maximal serum concentrations is 0.5 to 1 hour [<a href="#rid18">18</a>]. For these reasons, it is preferable to administer pdC1-INH as close in time (less than six hours) to the procedure as possible. </p><p class="headingAnchor" id="H458613159"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8998" href="/z/d/drug information/8998.html" rel="external">pdC1-INH</a> concentrate as a single prophylactic agent is generally accepted as effective based upon retrospective series and observational studies [<a href="#rid8">8,9,14,19,20</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>In one series, 33 adults and 8 children received 1000 units of <a class="drug drug_general" data-topicid="8998" href="/z/d/drug information/8998.html" rel="external">pdC1-INH</a> within the 24 hours preceding 91 dental and medical procedures [<a href="#rid14">14</a>]. Angioedema occurred in only 2 percent of procedures. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Preprocedure treatment with Cinryze was evaluated in an open-label study. A single, 1000-U dose was administered before 96 percent of the procedures (56 percent were dental, and 44 percent involved surgery or a diagnostic intervention); HAE attacks did not occur after 72 hours of C1-INH<sub> </sub>administration in 98 percent of the procedures [<a href="#rid14">14</a>]. </p><p></p><p>A <a class="drug drug_general" data-topicid="96337" href="/z/d/drug information/96337.html" rel="external">recombinant human C1 inhibitor</a> (rhC1-INH) preparation, conestat alfa (Ruconest in Europe and the United States, Rhucin in other countries) is also available. It has not been approved for prophylaxis, although rhC1-INH given intravenously one hour prior to the procedure has also been used successfully for short-term prophylaxis in case reports and a retrospective multicenter study [<a href="#rid21">21,22</a>]. The half-life (three hours) of the recombinant product is significantly shorter than that of the plasma-derived product (30 to 39 hours), and its efficacy for short-term prophylaxis may not be identical.</p><p class="headingAnchor" id="H3814766922"><span class="h3">Adverse effects</span><span class="headingEndMark"> — </span>Side effects of C1-INH concentrate are rare and include headache, nausea, fever, and anaphylaxis [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H3814766942"><span class="h2">Attenuated androgens</span><span class="headingEndMark"> — </span>Synthetic 17-alpha-alkylated androgens ("attenuated" or anabolic androgens) include <a class="drug drug_general" data-topicid="9321" href="/z/d/drug information/9321.html" rel="external">danazol</a>, stanozolol, <a class="drug drug_general" data-topicid="129317" href="/z/d/drug information/129317.html" rel="external">tibolone</a>, and <a class="drug drug_general" data-topicid="9640" href="/z/d/drug information/9640.html" rel="external">methyltestosterone</a>. The choice of androgen is based largely upon availability, since differences among drugs have not been well-characterized. Danazol is widely available throughout the world. Stanozolol is not produced commercially in the United States, although it is available by prescription and can be compounded by individual pharmacies. Tibolone may be less virilizing than other agents [<a href="#rid24">24-26</a>]. Methyltestosterone is another alternative [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H3814767019"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>Small, uncontrolled studies and individual case reports suggest that attenuated androgens are effective for short-term prophylaxis [<a href="#rid28">28,29</a>]. As an example, attacks were completely prevented in 12 patients with a history of angioedema after dental procedures who were administered <a class="drug drug_general" data-topicid="9321" href="/z/d/drug information/9321.html" rel="external">danazol</a> (600 mg/day) four days before and four days after various procedures [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H3814767065"><span class="h3">Dosing</span><span class="headingEndMark"> — </span>There are several approaches to dosing attenuated androgens for short-term prophylaxis, and no comparative data exist to recommend one approach over another. <a class="drug drug_general" data-topicid="9321" href="/z/d/drug information/9321.html" rel="external">Danazol</a> is used in the following examples, although equivalent doses of other attenuated androgens as well as similar timeframes are mentioned. In the United States, danazol and stanozolol are FDA-approved for prophylaxis in patients with HAE, while the other androgens are not. For patients already on long-term attenuated androgens, the doses may be increased temporarily to those described below.</p><p class="bulletIndent1"><span class="glyph">●</span>For patients not already taking androgens, <a class="drug drug_general" data-topicid="9321" href="/z/d/drug information/9321.html" rel="external">danazol</a> at a dose of 400 to 600 mg/day or an equivalent androgen at a comparable dose may be given for five days before and two to three days after a procedure  (<a class="graphic graphic_table graphicRef83117" href="/z/d/graphic/83117.html" rel="external">table 1</a>) [<a href="#rid3">3,4,30</a>]. Lower, weight-based dosing is advised (2.5 to 10 mg/kg) when children have to be treated, although the use of androgens in children should be avoided whenever possible.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stanozolol is another agent with which the authors of this topic have experience. Adult dosing is 4 to 6 mg daily for five days before and two to three days after (2 mg stanozolol is approximately equivalent to 200 mg of <a class="drug drug_general" data-topicid="9321" href="/z/d/drug information/9321.html" rel="external">danazol</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients already taking androgens regularly, the dose may be increased to 400 to 600 mg daily for five days before and two to three days after a procedure.</p><p></p><p>These recommendations are based upon the assumption that for the individual patient in question, a dose of this magnitude or less has been effective in the past. If not, a higher effective dose must be determined for that patient.</p><p class="headingAnchor" id="H3814767102"><span class="h3">Adverse effects and contraindications</span><span class="headingEndMark"> — </span>Short-term attenuated androgen therapy (ie, one or two weeks) is well-tolerated by most postpubertal males and by many female patients as well because the side effects are of minor significance when attenuated androgens are used only briefly. However, elevations in transaminases have been observed when excessively large doses were given (eg, 4 to 16 mg of stanozolol daily in adults) [<a href="#rid31">31</a>]. These doses are not routinely used. A pediatric endocrinology specialist should be consulted if androgens are used in children.</p><p>There are no absolute contraindications to short-term prophylaxis with attenuated androgens, except possibly pregnancy, since androgens can cause virilization of female fetuses. Androgens were even used successfully in pregnant women with HAE in the past when other options were lacking, with close collaboration with an obstetrician. However, with the alternative therapies available, attenuated androgen use in pregnancy is best avoided altogether [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H3814767136"><span class="h2">Plasma products</span><span class="headingEndMark"> — </span>Human plasma contains C1-INH and can be used for short-term prophylaxis. However, the efficacy is not as well-established as that of C1-INH preparations. Replacement plasma is available in two forms: fresh frozen plasma (FFP) and solvent/detergent-treated plasma (S/D plasma). (See  <a class="medical medical_review" href="/z/d/html/7920.html" rel="external">"Clinical use of plasma components", section on 'Plasma products'</a>.)</p><p class="headingAnchor" id="H3814767172"><span class="h3">Dosing and timing</span><span class="headingEndMark"> — </span>The usual dose is 2 units for adults, 10 mL/kg in children, given one to two hours before the procedure. Optimal dosing has not been studied.</p><p class="headingAnchor" id="H3814767178"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>The efficacy of FFP for short-term prophylaxis is supported by several case reports and observational series [<a href="#rid32">32-35</a>]. In a review of the literature, 148 cases were identified in which FFP was administered as short-term prophylaxis, with six instances of angioedema [<a href="#rid32">32</a>]. No controlled trials have been performed.</p><p>The efficacy data on S/D plasma are only anecdotal. Studies would be needed to demonstrate that it is an equivalent substitute for FFP, since S/D treatment may theoretically inactivate some proteins, and the effect on C1-INH concentration has not been reported. (See  <a class="medical medical_review" href="/z/d/html/7929.html" rel="external">"Pathogen inactivation of blood products", section on 'Potential limitations'</a>.)</p><p class="headingAnchor" id="H3814767260"><span class="h3">Adverse effects</span><span class="headingEndMark"> — </span>FFP has been associated acutely with urticaria, anaphylactic shock, and hemolysis, although we are not aware of reports of these events in patients with HAE. (See  <a class="medical medical_review" href="/z/d/html/7920.html" rel="external">"Clinical use of plasma components"</a>.)</p><p>The primary concern with plasma products is disease transmission and the risks of this must be presented to the patient.</p><p class="bulletIndent1"><span class="glyph">●</span>S/D treatment inactivates enveloped viruses (such as human immunodeficiency virus [HIV], human T lymphotropic virus, and hepatitis B and C) but not prions or nonenveloped viruses (eg, hepatitis A, parvovirus). (See  <a class="medical medical_review" href="/z/d/html/7929.html" rel="external">"Pathogen inactivation of blood products", section on 'Potential benefits'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>FFP does not undergo processing to remove infectious agents. The risk of disease transmission from FFP and other plasma products is presented in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/7946.html" rel="external">"Blood donor screening: Laboratory testing", section on 'Infectious disease screening and surveillance'</a> and  <a class="medical medical_review" href="/z/d/html/7950.html" rel="external">"Blood donor screening: Medical history", section on 'Screening for infectious risks'</a>.)</p><p></p><p class="headingAnchor" id="H1942107638"><span class="h1">OUR APPROACH</span><span class="headingEndMark"> — </span>Several guidelines and practice parameters on the treatment of HAE have been published [<a href="#rid3">3,4,30,36-41</a>]. However, few studies have evaluated short-term prophylaxis specifically, and recommendations in the guidelines are largely extrapolated from data of efficacy of different agents in long-term prophylaxis. The approach presented in this topic review is consistent with available guidelines, although it is largely based on the experience of the authors and editors.</p><p>As mentioned previously, angioedema triggered by a procedure usually occurs within 48 hours of the procedure, so it is important that plans be made for both the procedure and the postprocedure period. Because angioedema does not typically develop during or immediately after the procedure, we do not insist that patients only receive dental care to hospital-based clinics or put other additional restrictions on them, provided on-demand therapy is accessible.</p><p class="headingAnchor" id="H3656544419"><span class="h2">General precautions</span></p><p class="bulletIndent1"><span class="glyph">●</span>Communication between the patient, specialist performing the procedure, and allergist/immunologist (or other HAE expert) is critical. Both the clinician performing the procedure and the patient should know how to reach the HAE expert clinician in case advice is needed. A printable form summarizing the acute treatment of HAE is available to assist in this communication  (<a class="graphic graphic_form graphicRef70252" href="/z/d/graphic/70252.html" rel="external">form 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ideally, two doses of an on-demand therapy should be available to patients undergoing procedures, and these doses should be available to the patient both in the clinic and for two to three days after the procedure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest that the patient be observed for at least two hours after the procedure, before being discharged home. However, as mentioned above, swelling related to the procedure may begin within the ensuring 48 hours, so patients must also have a plan in place to access on-demand therapy if needed.</p><p></p><p class="headingAnchor" id="H3960745245"><span class="h2">High-risk procedures</span><span class="headingEndMark"> — </span>There are two principal approaches for preprocedural prophylaxis for high-risk procedures, such as oral surgery and intubation  (<a class="graphic graphic_table graphicRef83117" href="/z/d/graphic/83117.html" rel="external">table 1</a>) [<a href="#rid30">30</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Plasma-derived C1 inhibitor (<a class="drug drug_general" data-topicid="8998" href="/z/d/drug information/8998.html" rel="external">pdC1-INH</a>) concentrate (20 units per kg) may be given one hour before the procedure, with two additional doses available for on-demand use if symptoms develop. Alternatively, <a class="drug drug_general" data-topicid="9035" href="/z/d/drug information/9035.html" rel="external">ecallantide</a> (a kallikrein inhibitor), <a class="drug drug_general" data-topicid="16808" href="/z/d/drug information/16808.html" rel="external">icatibant</a> (a bradykinin B2-receptor antagonist), and <a class="drug drug_general" data-topicid="96337" href="/z/d/drug information/96337.html" rel="external">recombinant human C1 inhibitor</a> (C1-INH) could be used if symptoms develop (although ecallantide and icatibant are not used <strong>before</strong> the procedure, as their efficacy as prophylaxis is not known). Dosing of pdC1-INH concentrate is discussed above. (See <a class="local">'C1 inhibitor concentrate'</a> above.)</p><p></p><p class="bulletIndent1">OR</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If <a class="drug drug_general" data-topicid="8998" href="/z/d/drug information/8998.html" rel="external">pdC1-INH</a> is not available, attenuated androgens may be given for five days before and two to three days after the procedure, administered as described below This option is usually reserved for patients who are known to tolerate attenuated androgens or have experience taking these drugs for long-term prophylaxis and for countries in which access to C1-INH, <a class="drug drug_general" data-topicid="16808" href="/z/d/drug information/16808.html" rel="external">icatibant</a>, and <a class="drug drug_general" data-topicid="9035" href="/z/d/drug information/9035.html" rel="external">ecallantide</a> is limited. (See <a class="local">'Attenuated androgens'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A third option, if none of the above therapies is available, is solvent/detergent-treated plasma (S/D plasma) or fresh frozen plasma (FFP). (See <a class="local">'Plasma products'</a> above.)</p><p></p><p class="headingAnchor" id="H2546017061"><span class="h2">Lower-risk procedures</span><span class="headingEndMark"> — </span>If on-demand therapies are available, then short-term prophylaxis may not be necessary. On-demand therapies include C1-INH concentrate, <a class="drug drug_general" data-topicid="16808" href="/z/d/drug information/16808.html" rel="external">icatibant</a>, or <a class="drug drug_general" data-topicid="9035" href="/z/d/drug information/9035.html" rel="external">ecallantide</a> (United States only). If on-demand therapies are not immediately available, we would administer attenuated androgen premedication, unless the individual tolerated that specific procedure in the past.</p><p class="headingAnchor" id="H732051712"><span class="h2">Emergency procedures</span><span class="headingEndMark"> — </span>In an emergency situation in which prophylaxis is indicated, C1-INH concentrate should be given, if available. If no acute therapies are available and there is not enough time for attenuated androgen pretreatment, plasma products (FFP or S/D plasma) may be given. (See <a class="local">'Plasma products'</a> above.)</p><p class="headingAnchor" id="H2377191601"><span class="h2">Travel to remote areas</span><span class="headingEndMark"> — </span>Patients traveling to remote areas who are not already receiving long-term prophylaxis may want to take extended short-term prophylaxis (such as attenuated androgens) temporarily and should also have on-demand medications that can be self-administered.</p><p class="headingAnchor" id="H682943229"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/104440.html" rel="external">"Society guideline links: Hereditary angioedema and other forms of nonhistaminergic angioedema"</a>.)</p><p class="headingAnchor" id="H3814767300"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>Patients can access detailed, patient-oriented information through the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.haea.org%2F&amp;token=sL%2Bp%2BgWoM5K8OZ3TcR7z2ToF1uVERDbCtFU1b2q4gXg%3D&amp;TOPIC_ID=101085" target="_blank">United States Hereditary Angioedema Association</a> and the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.haei.org%2F&amp;token=sL%2Bp%2BgWoM5K8OZ3TcR7z2V3i54LW3H1KTfBt%2Bpz0vSs%3D&amp;TOPIC_ID=101085" target="_blank">International Patient Organization for C1 Inhibitor Deficiencies</a>.</p><p class="headingAnchor" id="H3814767306"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with hereditary angioedema (HAE), "short-term" or "preprocedural" prophylaxis refers to the administration of medications briefly before a procedure or stressful event that is likely to precipitate an episode of angioedema. It may also be given to patients traveling to remote areas in which they may not be able to access health care. (See <a class="local">'Indications for short-term prophylaxis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Angioedema typically begins within 48 hours of a triggering event or procedure. Patients should be advised that swelling often occurs one day or so <strong>after</strong> the procedure, and a specific plan of treatment should be in place for symptoms that arise during this period. (See <a class="local">'Typical timing of onset of symptoms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some procedures, such as oral surgery, intubation, endoscopy, and dental work that involves injections or cutting of tissues, reliably trigger symptoms in most patients. However, individuals vary in their susceptibility to HAE attacks. If a patient has had symptoms with a given procedure, then it should be considered high risk for that patient, and prophylaxis should be administered for future similar procedures. (See <a class="local">'Risk associated with specific procedures'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>None of the available therapies confer complete protection from an HAE attack, and the supervising clinician must be prepared to recognize and manage angioedema with on-demand therapies immediately available. (See <a class="local">'General precautions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients undergoing high-risk procedures (eg, major dental procedures, surgery, intubation, endoscopy), we recommend administering prophylactic therapy  (<a class="graphic graphic_table graphicRef83117" href="/z/d/graphic/83117.html" rel="external">table 1</a>) (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>) (see <a class="local">'High-risk procedures'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest giving plasma-derived C1 inhibitor (<a class="drug drug_general" data-topicid="8998" href="/z/d/drug information/8998.html" rel="external">pdC1-INH</a>) concentrate (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We prefer weight-based dosing (ie, 20 units per kg). This should be injected as close in time to the procedure as is feasible (optimally within the hour before the procedure). At least two additional doses of an on-demand therapy (C1 inhibitor [C1-INH], <a class="drug drug_general" data-topicid="16808" href="/z/d/drug information/16808.html" rel="external">icatibant</a>, or <a class="drug drug_general" data-topicid="9035" href="/z/d/drug information/9035.html" rel="external">ecallantide</a>) should be available to the patient in case symptoms develop either during the procedure or during the two to three days following the procedure. (See <a class="local">'C1 inhibitor concentrate'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If <a class="drug drug_general" data-topicid="8998" href="/z/d/drug information/8998.html" rel="external">pdC1-INH</a> concentrate is not available, we suggest premedication with attenuated androgens (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). A representative regimen is <a class="drug drug_general" data-topicid="9321" href="/z/d/drug information/9321.html" rel="external">danazol</a> (10 mg/kg per day to a maximum of 600 mg/day), beginning five days before and extending for two to three days after the procedure. (See <a class="local">'Attenuated androgens'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients undergoing low-risk procedures, we suggest <strong>not</strong> administering attenuated androgens in advance, provided C1-INH concentrate, <a class="drug drug_general" data-topicid="9035" href="/z/d/drug information/9035.html" rel="external">ecallantide</a> (United States), or <a class="drug drug_general" data-topicid="16808" href="/z/d/drug information/16808.html" rel="external">icatibant</a> is immediately available to treat any symptoms that arise  (<a class="graphic graphic_table graphicRef83117" href="/z/d/graphic/83117.html" rel="external">table 1</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). If one of these acute therapies is not immediately available, we would administer attenuated androgen premedication, unless the patient tolerated that specific procedure in the past. (See <a class="local">'Lower-risk procedures'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an emergency situation in which prophylaxis is indicated but no acute therapies are available and there is not enough time for attenuated androgen pretreatment, plasma products (fresh frozen plasma [FFP] or solvent/detergent-treated plasma [S/D plasma]) may be given. (See <a class="local">'Emergency procedures'</a> above.)</p><p></p><p class="headingAnchor" id="H3814767528"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Marco Cicardi, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy 2014; 69:602.</a></li><li><a class="nounderline abstract_t">Bhardwaj N, Craig TJ. Treatment of hereditary angioedema: a review (CME). Transfusion 2014; 54:2989.</a></li><li><a class="nounderline abstract_t">Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2017 revision and update. Allergy 2018; 73:1575.</a></li><li><a class="nounderline abstract_t">Betschel S, Badiou J, Binkley K, et al. The International/Canadian Hereditary Angioedema Guideline. Allergy Asthma Clin Immunol 2019; 15:72.</a></li><li><a class="nounderline abstract_t">Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med 2008; 359:1027.</a></li><li><a class="nounderline abstract_t">Magerl M, Frank M, Lumry W, et al. Short-term prophylactic use of C1-inhibitor concentrate in hereditary angioedema: Findings from an international patient registry. Ann Allergy Asthma Immunol 2017; 118:110.</a></li><li><a class="nounderline abstract_t">Farkas H, Zotter Z, Csuka D, et al. Short-term prophylaxis in hereditary angioedema due to deficiency of the C1-inhibitor--a long-term survey. Allergy 2012; 67:1586.</a></li><li><a class="nounderline abstract_t">Zanichelli A, Ghezzi M, Santicchia I, et al. Short-term prophylaxis in patients with angioedema due to C1-inhibitor deficiency undergoing dental procedures: An observational study. PLoS One 2020; 15:e0230128.</a></li><li><a class="nounderline abstract_t">Bork K, Hardt J, Staubach-Renz P, Witzke G. Risk of laryngeal edema and facial swellings after tooth extraction in patients with hereditary angioedema with and without prophylaxis with C1 inhibitor concentrate: a retrospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011; 112:58.</a></li><li><a class="nounderline abstract_t">Aygören-Pürsün E, Martinez Saguer I, Kreuz W, et al. Risk of angioedema following invasive or surgical procedures in HAE type I and II--the natural history. Allergy 2013; 68:1034.</a></li><li><a class="nounderline abstract_t">Frank MM. 8. Hereditary angioedema. J Allergy Clin Immunol 2008; 121:S398.</a></li><li><a class="nounderline abstract_t">Marqués L, Domingo D, Maravall FJ, Clotet J. Short-term prophylactic treatment of hereditary angioedema with icatibant. Allergy 2010; 65:137.</a></li><li><a class="nounderline abstract_t">Caballero T, Farkas H, Bouillet L, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol 2012; 129:308.</a></li><li><a class="nounderline abstract_t">Grant JA, White MV, Li HH, et al. Preprocedural administration of nanofiltered C1 esterase inhibitor to prevent hereditary angioedema attacks. Allergy Asthma Proc 2012; 33:348.</a></li><li><a class="nounderline abstract_t">Farkas H, Martinez-Saguer I, Bork K, et al. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. Allergy 2017; 72:300.</a></li><li><a class="nounderline abstract_t">Longhurst H, Cicardi M, Craig T, et al. Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor. N Engl J Med 2017; 376:1131.</a></li><li><a class="nounderline abstract_t">Bernstein JA, Ritchie B, Levy RJ, et al. Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacks. Ann Allergy Asthma Immunol 2010; 105:149.</a></li><li><a class="nounderline abstract_t">Martinez-Saguer I, Rusicke E, Aygören-Pürsün E, et al. Pharmacokinetic analysis of human plasma-derived pasteurized C1-inhibitor concentrate in adults and children with hereditary angioedema: a prospective study. Transfusion 2010; 50:354.</a></li><li><a class="nounderline abstract_t">Leimgruber A, Jaques WA, Spaeth PJ. Hereditary angioedema: uncomplicated maxillofacial surgery using short-term C1 inhibitor replacement therapy. Int Arch Allergy Immunol 1993; 101:107.</a></li><li><a class="nounderline abstract_t">Langston D, Weiner J, Fary W. C1-esterase inhibitor concentrate prevents upper airways obstruction in hereditary angio-oedema. Med J Aust 1994; 164:383.</a></li><li><a class="nounderline abstract_t">Farkas H, Kohalmi KV, Veszeli N, et al. Successful prophylaxis with recombinant human C1 inhibitor in a patient with hereditary angioedema. Ann Allergy Asthma Immunol 2015; 114:64.</a></li><li><a class="nounderline abstract_t">Valerieva A, Staevska M, Jesenak M, et al. Recombinant human C1 esterase inhibitor as short-term prophylaxis in patients with hereditary angioedema. J Allergy Clin Immunol Pract 2020; 8:799.</a></li><li><a class="nounderline abstract_t">Cicardi M, Zingale L. How do we treat patients with hereditary angioedema. Transfus Apher Sci 2003; 29:221.</a></li><li><a class="nounderline abstract_t">Ott HW, Mattle V, Hadziomerovic D, et al. Treatment of hereditary angioneurotic oedema (HANE) with tibolone. Clin Endocrinol (Oxf) 2007; 66:180.</a></li><li><a class="nounderline abstract_t">FOX M, MINOT AS, LIDDLE GW. Oxandrolone: a potent anabolic steroid of novel chemical configuration. J Clin Endocrinol Metab 1962; 22:921.</a></li><li><a class="nounderline abstract_t">Church JA. Oxandrolone treatment of childhood hereditary angioedema. Ann Allergy Asthma Immunol 2004; 92:377.</a></li><li><a class="nounderline abstract_t">Sheffer AL, Fearon DT, Austen KF. Methyltestosterone therapy in hereditary angioedema. Ann Intern Med 1977; 86:306.</a></li><li><a class="nounderline abstract_t">Farkas H, Gyeney L, Gidófalvy E, et al. The efficacy of short-term danazol prophylaxis in hereditary angioedema patients undergoing maxillofacial and dental procedures. J Oral Maxillofac Surg 1999; 57:404.</a></li><li><a class="nounderline abstract_t">Hardie J, Ringland T, Yang WH, Wagner V. Potentially fatal hereditary angioedema: a review and case report. J Can Dent Assoc 1990; 56:1096.</a></li><li><a class="nounderline abstract_t">Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010; 6:24.</a></li><li><a class="nounderline abstract_t">Sheffer AL, Fearon DT, Austen KF. Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. J Allergy Clin Immunol 1981; 68:181.</a></li><li><a class="nounderline abstract_t">Prematta M, Gibbs JG, Pratt EL, et al. Fresh frozen plasma for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol 2007; 98:383.</a></li><li><a class="nounderline abstract_t">Atkinson JC, Frank MM. Oral manifestations and dental management of patients with hereditary angioedema. J Oral Pathol Med 1991; 20:139.</a></li><li><a class="nounderline abstract_t">Degroote DF, Smith GL, Huttula GS. Acute airway obstruction following tooth extraction in hereditary angioedema. J Oral Maxillofac Surg 1985; 43:52.</a></li><li><a class="nounderline abstract_t">Phillips KM, Glick M, Cohen SG. Hereditary angioedema: report of case. Spec Care Dentist 1989; 9:23.</a></li><li><a class="nounderline abstract_t">Cicardi M, Bork K, Caballero T, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012; 67:147.</a></li><li><a class="nounderline abstract_t">Bowen T, Brosz J, Brosz K, et al. Management of hereditary angioedema: 2010 Canadian approach. Allergy Asthma Clin Immunol 2010; 6:20.</a></li><li><a class="nounderline abstract_t">Zuraw BL, Bernstein JA, Lang DM, et al. A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema. J Allergy Clin Immunol 2013; 131:1491.</a></li><li><a class="nounderline abstract_t">Zuraw BL, Banerji A, Bernstein JA, et al. US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. J Allergy Clin Immunol Pract 2013; 1:458.</a></li><li><a class="nounderline abstract_t">Bork K. An evidence based therapeutic approach to hereditary and acquired angioedema. Curr Opin Allergy Clin Immunol 2014; 14:354.</a></li><li><a class="nounderline abstract_t">Betschel S, Badiou J, Binkley K, et al. Canadian hereditary angioedema guideline. Allergy Asthma Clin Immunol 2014; 10:50.</a></li></ol></div><div id="topicVersionRevision">Topic 101085 Version 19.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24673465" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24735226" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Treatment of hereditary angioedema: a review (CME).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29318628" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The international WAO/EAACI guideline for the management of hereditary angioedema-The 2017 revision and update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31788005" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The International/Canadian Hereditary Angioedema Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18768946" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical practice. Hereditary angioedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27865714" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Short-term prophylactic use of C1-inhibitor concentrate in hereditary angioedema: Findings from an international patient registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23025435" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Short-term prophylaxis in hereditary angioedema due to deficiency of the C1-inhibitor--a long-term survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32163480" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Short-term prophylaxis in patients with angioedema due to C1-inhibitor deficiency undergoing dental procedures: An observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21601496" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Risk of laryngeal edema and facial swellings after tooth extraction in patients with hereditary angioedema with and without prophylaxis with C1 inhibitor concentrate: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23968383" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Risk of angioedema following invasive or surgical procedures in HAE type I and II--the natural history.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18241690" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : 8. Hereditary angioedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20078507" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Short-term prophylactic treatment of hereditary angioedema with icatibant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22197274" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22856635" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Preprocedural administration of nanofiltered C1 esterase inhibitor to prevent hereditary angioedema attacks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27503784" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28328347" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20674826" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19788511" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pharmacokinetic analysis of human plasma-derived pasteurized C1-inhibitor concentrate in adults and children with hereditary angioedema: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8499768" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Hereditary angioedema: uncomplicated maxillofacial surgery using short-term C1 inhibitor replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : C1-esterase inhibitor concentrate prevents upper airways obstruction in hereditary angio-oedema</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25454013" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Successful prophylaxis with recombinant human C1 inhibitor in a patient with hereditary angioedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31437566" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Recombinant human C1 esterase inhibitor as short-term prophylaxis in patients with hereditary angioedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14572813" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : How do we treat patients with hereditary angioedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17223985" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Treatment of hereditary angioneurotic oedema (HANE) with tibolone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13894381" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Oxandrolone: a potent anabolic steroid of novel chemical configuration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15049404" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Oxandrolone treatment of childhood hereditary angioedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/320930" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Methyltestosterone therapy in hereditary angioedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10199492" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The efficacy of short-term danazol prophylaxis in hereditary angioedema patients undergoing maxillofacial and dental procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2149524" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Potentially fatal hereditary angioedema: a review and case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20667127" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6790595" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Clinical and biochemical effects of stanozolol therapy for hereditary angioedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17458436" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Fresh frozen plasma for the treatment of hereditary angioedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1828083" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Oral manifestations and dental management of patients with hereditary angioedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3855319" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Acute airway obstruction following tooth extraction in hereditary angioedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2533708" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Hereditary angioedema: report of case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22126399" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20667123" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Management of hereditary angioedema: 2010 Canadian approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23726531" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24565617" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24983294" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : An evidence based therapeutic approach to hereditary and acquired angioedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25352908" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Canadian hereditary angioedema guideline.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
